***Background.*** The polymorphism of the accessory gene regulator (*agr*) of methicillin-resistant *Staphylococcus aureus (MRSA)* is known to play an important role in controlling the production of virulence factors. Notably, infections caused by MRSA with *agr-*II expression are shown to be predictive of vancomycin therapy failure. However, the impact of *agr-*II expression on mortality of patients receiving vancomycin therapy for severe MRSA infections is not well established. The aim of this study was to evaluate the association between *agr-*II expression and 30-day mortality among critically ill patients receiving vancomycin therapy for hospital-acquired MRSA bacteremia.

***Methods.*** A retrospective cohort was performed at a 30-bed general intensive care unit (ICU) of a tertiary hospital in southern Brazil. All cases of documented hospital-acquired MRSA bacteremia treated with vancomycin in the ICU setting between May 2009 and November 2011 were evaluated. Cox regression was performed to evaluate whether *agr-*II expression (determined by PCR) was associated with 30-day mortality. Covariates included age, presence of immunossuppression, APACHE-II score, initial C-reactive protein (CRP) plasma levels, initial serum creatinine levels, vancomycin minimum inhibitory concentration, vancomycin serum levels and time to effective antibiotic administration.

***Results.*** In total, 21 patients were evaluated during the study period. The prevalence of *agr-*II expression was 38% (8 patients). The median APACHE-II of the study population was 23 (IQR, 19 to 31). The overall cohort mortality was 61% (13 patients). After multivariate analysis, initial plasma CRP (*P* = 0.01), initial serum creatinine (*P* = 0.03) and expression of *agr-*II (*P* = 0.02) were independently associated with the 30-day mortality. Patients receiving vancomycin therapy for bacteremia due to MRSA with *agr-*II expression had their hazard of death increased by 6.6 times (95%CI, 1.2-37.0) when compared with those with bacteremia by MRSA without *agr-*II expression.

***Conclusion.*** Expression of *agr-*II poses risk for mortality in critically ill patients receiving vancomycin for hospital-acquired MRSA bacteremia. Alternative antimicrobial agents including daptomycin and linezolid for treatment of MRSA bacteremia expressing *agr-*II should be considered in this setting.
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